![Pieter H. Reitsma](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Pieter H. Reitsma
Geen lopende functies
Loopbaan van Pieter H. Reitsma
Eerdere bekende functies van Pieter H. Reitsma
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Varmx BV
![]() Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Hoofd Techniek/Wetenschap/O&O | - | 08-03-2023 |
Oprichter | - | 08-03-2023 |
Statistieken
Internationaal
Nederland | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectoraal
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Varmx BV
![]() Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
- Beurs
- Insiders
- Pieter H. Reitsma
- Ervaring